Stocks
INTERCEPT PHARMICPT
HealthcareBiotechnology
A biopharmaceutical company focused on developing oral therapies for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Its lead product, obeticholic acid, received accelerated approval for PBC, and the company has been a key player in the NASH drug development race. Investors track it for its pipeline progress and regulatory milestones in a high-demand therapeutic area.
Congressional Interest in INTERCEPT PHARM (ICPT)
2 members of Congress have disclosed 2 trades in INTERCEPT PHARM (ICPT), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
2
Buys
1
Sells
1
Who in Congress Is Trading ICPT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-07-05 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2011-04-01 | JAMES B. RENACCI | buy | $1,320.10 |